Tuition fees, on-site accommodation and transport will be covered by FOCIS, thanks to an educational grant by Celgene.
Judit Anido Folgueira
Judit has led the growth of Mosaic Biomedicals as CEO since its inception in 2012 until its merger with Northern Biologics in 2016, and as General Manager thereafter. In addition, Judit is VP of Operations and Corporate Affairs at Northern Biologics, a Toronto-based innovative biotechnology company dedicated to developing novel therapeutic antibodies for the treatment of oncology and fibrosis. Prior to Mosaic, Judit was an Associate in the Pipeline and Portfolio Planning team, collaborating with the Oncology and Hematology Franchise at Genentech Inc. (CA, US).
Judit holds a Masters in Business Administration (MBA) from Duke University (NC, US) with a certification in Health Sector Management and focus in Entrepreneurship and Innovation. In addition, she received her PhD from the University of Barcelona (Spain) and has over 10 years’ experience in translational oncology at the Vall d’Hebron Institute of Oncology (Spain). Judit is a recipient of merit-based scholarships from the Spanish Association Against Cancer (AECC), Rafael del Pino Foundation, Caja Madrid Foundation and Duke University’s Julian Connally Scholarship.
Elaine is currently the Executive Director of New Products and Early Commercial Development for the Immunology & Inflammation (I&I) franchise at Celgene. She and her team provide commercial direction for new products in the pipeline from Discovery to Phase 3 across Rheumatology, Dermatology, Neurology and Fibrosis. They also lead commercial business development strategy and due diligence. Elaine joined Celgene in 2015 working in a pivotal role in Global Marketing for Otezla.
Prior to joining Celgene, she spent over 15 years at J&J working on commercialized and development-stage brands in both U.S. and Global Marketing. She began her career at Boehringer Mannheim (now Roche) in a variety of roles in market research and analytics. Elaine received her M.B.A. in Biotechnology and Healthcare from Penn State. She is an adjunct professor at Jefferson University, and also lectures at Rutgers University, focusing on the role of marketing in drug development.
Iain heads Cambridge Enterprise’s Life Science team. The team is responsible for technology in fields as diverse as therapeutics, diagnostics, biofuels, IVF and epigenetics. Recent spin-outs from Cambridge University include Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics, Z-factor, Phoremost and Predictimmue; XO1 was sold to Janssen for an undisclosed sum. Iain led discussions with GSK in respect of the University of Cambridge–GSK open innovation drug discovery initiative based at the Stevenage Bioscience Catalyst, founded (with others) Apollo Therapeutics an innovative vehicle for developing early stage therapeutic opportunities from three Universities (Cambridge, University College London and Imperial College) and led the creation of the recently announced Ceres, a funding partnership of technology in the Agritech sector.
Daphné DEROUANE has received her doctorate in Organic Chemistry in 1997 from the Catholic University of Louvain (Louvain-La-Neuve, Belgium). After receiving various trainings in European Patent Law, she has worked as patent counsel in the Intellectual Property Department of Asahi Glass Company (AGC) Europe and the Technology Transfer Office of the University of Namur, before joining the Intellectual Property Department of UCB Pharma SA in 2004.
Since then she has been providing a wide range of IP support to the UCB R&D groups including patent drafting, patent prosecution, freedom-to-operate opinions and drafting/negotiation of agreements related to drug development.
Daphné has also been very active in providing IP support to Public Private Partnerships operating under European frameworks, such as FP7 and the Innovative Medicines Initiative (IMI). Early 2009, she joined the European Federation Pharmaceutical Industry Association (EFPIA) IMI IP Task Force and in 2012 participated to the negotiations of the IP rules underlying the IMI 2 Joint Undertaking operating under the overarching HORIZON 2020 framework.
King’s Commercialisation Institute
King’s College London
Mike founded the King’s Commercialisation Institute (KCI) in 2012. The Institute provides University staff with commercial translation skills and accelerates the transition of life science research to product development through to engagement with industry and private investors. KCI integrates industrial style portfolio management techniques within the University setting, selecting projects for support and funding by the King’s Health Accelerator which KCI manages.
Before joining King’s, Mike’s 31 years of pharmaceutical industry experience spanned the globe including senior US and global management roles. Mike led the commercial development of three blockbuster (annual sales >$1bn) antiviral products (Retrovir (HIV), Valtrex (Herpes) & Viread (HIV)) at Wellcome, GlaxoSmithKline and Gilead Sciences. He was subsequently CEO of Molecular Skincare in the UK which he sold to York Pharma and joined its Board as Commercial Director raising £50mil in funding and completing three corporate acquisitions.
Ignacio Anegon received his MD degree in 1982 and trained as a postdoc at the University Hospital of Barcelona, Spain, and as an Associate Scientist at the University of Pennsylvania, USA. He has been a permanent researcher at the INSERM since 1989. He has been team leader since 1995, Director of the INSERM Center for Research in Transplantation and Immunology in Nantes, France (2008-2017), and of the FOCIS Center of Excellence of Nantes University (2008 - Present) and of the Labex ImmunologyGraftOncology (2016 - Present). He is also Director of the “Rat Transgenic Nantes” platform that generates transgenic and knockout rats (2001 - Present). He has been editor-in-chief of Current Gene Therapy (2004 - 2015) and is a member of various editorial boards for journals such as Transplantation and Transgenic Research. He has edited three books in the series titled “Methods in Molecular Biology”. His research areas are transplantation tolerance, gene transfer and the generation of genetically modified animals. He has published over 235 manuscripts with 219 of them in PubMed. He is part of several Scientific Advisory Boards for various funding agencies, international academic societies, research centers and biotechnology companies.
Ben Owens is an immunologist with translational research expertise in chronic inflammation and autoimmunity. He is Head of Business Development and a member of the Executive Leadership Team at EUSA Pharma, a rapidly growing EU and US commercial-stage Immuno-oncology Company founded in March 2015. Ben has led a transformative programme of global product licensing transactions and been instrumental in developing the company from start-up stage to the commercialisation of antibody and small molecule therapeutics, with 2018 revenues approaching $100 Million. He is also co-Founder of ImmElpis Pharma, a University of Oxford spin-out company developing a novel therapeutic target and biomarker for Inflammatory Bowel Disease based on patented technology that he co-invented. Ben has significant experience of healthcare entrepreneurship at the academia-industry interface and is an alumnus of the Celgene/INSEAD ECA 2013 Programme. Ben trained in Immunology at the Universities of Bristol (BSc 2007) and York (PhD 2010), and has published widely in the field of Immune Regulation and Stromal Immunology. He previously held a Wellcome Trust Postdoctoral Fellowship and a UCB Pharma Research Fellowship at the University of Oxford, where he remains a visiting Lecturer in medicine.
Lionel Carnot is a Managing Director of Bay City Capital, joining the firm in 2005 after having been extensively involved in the firm’s activities as part of The Pritzker Organization since 2000. Mr Carnot is based in Bay City Capital’s office in Basel, Switzerland, where he manages the firm’s European activities. He contributes significant pharmaceutical and diagnostics, transactional and strategic expertise to Bay City Capital’s investment portfolio. Prior to The Pritzker Organization, Mr Carnot was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly and several sales and marketing positions at Sanofi-Aventis. Mr Carnot was also a strategy and management consultant to the biopharmaceutical industry while at Booz Allen & Hamilton, and Accenture Strategic Services. Mr Carnot holds an MBA with Distinction from INSEAD and an MSc in Molecular Biology from the University of Geneva.
Olivier Van Obberghen
Olivier Van Obberghen is a member of the Brussels Bar and Co-Founder of the boutique law firm QUINZ, where he Co-Heads the Life Sciences Department together with Pieter Wyckmans. Olivier assists Life Science companies on a variety of strategic transactional and regulatory questions notably on R&D, supply chain, product divestments (M&A), and licensing structures. He also provides expert training on a broad range of transactional and regulatory matters in relation to clinical development. Olivier Van Obberghen started his career at Cleary Gottlieb Steen and Hamilton, and was seconded for almost 2 years to the legal department of UCB.
Pieter Wyckmans started his career at Linklaters and is now a member of the Brussels Bar and Co-Founder of the boutique law firm QUINZ, where he Co-Heads the Life Sciences Department together with Olivier Van Obberghen. He combines years of experience as an M&A lawyer, with years of experience as in-house counsel of multi-nationals active within the pharmaceutical and chemical industry. His practice focuses on advising clients on national and international transactions (with a particular focus on IP monetization deals and R&D agreements) and pharma regulatory law (life cycle management, market access and compliance).
Andrew Hall joined Celgene in 2014 to lead the development of its Inflammation and Immunology pipeline as the Commercial Head of New Products and Strategic Analytics. Prior to joining Celgene, Andrew led product development for Women’s Health at Merck (MSD outside of the US) and, over the span of 15 years, has held leadership roles in Emerging Markets, Japan, Australia, and Malaysia. He has extensive experience in global commercial strategy, drug development, and end-to-end lifecycle management, as well as mergers, acquisitions and business development. He holds a Masters of Marketing (RMIT) and a BMedSci(hons) from Melbourne University, Australia.
Sara is currently an independent life sciences investor. Sara serves on the advisory board of Springboard Enterprises, LaCaixa Foundation and Biofit. She also serves as scientific expert for the National Institutes of Science (NIH) and Horizon2020, and she is faculty at the IBE (Institute for Biomedical Entrepreneurship).
Between 2013-2018, Sara was Principal at Sofinnova Partners. During this period, Sara was involved in various investments such as Delinia Bio (sold to Celgene for $785M), ProQR Therapeutics [PRQR] and Auris Medical [EARS]. She on the Board of TM3 Therapeutics, Enyo Pharma, TrophyNOD and Delinia Bio.
Prior to joining Sofinnova Partners, Sara was an associate in the Licensing and M&A team at Onyx Pharmaceuticals (now Amgen) in California.
Sara spent +6 years in the pharmaceutical industry with Solvay and Abbott Laboratories in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of 3 IND packages.
Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed fourth-generation several transition state inhibitors for the enzyme PNP. One of these compounds, Ulodesine (DADMe-ImmucillinH) entered clinical trials in gout.
Sara received her PhD in Chemistry from the University of Manchester, UK. She has published fifteen peer-reviewed articles and 1 patent (US20110237569). In addition, Sara also holds an MBA from INSEAD (2012).
Timothy Radstake MD, PhD, joined the UMC Utrecht in 2012 as professor of Translational Immunology within the departments of Rheumatology & Clinical Immunology and on the Laboratory of Translational Immunology. After receiving his MD (2000) and PhD (2003) (Prof. W.B. van dan Berg / Prof. P.L.C.M. van Riel) he started his clinical training as a rheumatologist and simultaneously started up his own research group on the role of genetic factors and dendritic cells in inflammatory diseases. From 2007–2008 he did a post-doctoral fellowship at the Scleroderma Centre of the Boston University School of Medicine (Prof. R. Lafyatis) from where he started the research line to decipher the role of the immune system in Scleroderma and other chronic inflammatory diseases.
Paul is multiple time winner of the INSEAD Dean’s Award for Excellence in Teaching. He is the creator of INSEAD’s start-up boot camp. Paul teaches entrepreneurship courses and is the lead professor on INSEAD’s popular elective "Your First Hundred Days", which teaches students how to turn around a failing company.
Paul has decades of work experience with start-ups, major technology companies, investment capital, consulting, and government initiatives. He has successfully worked in every corner of a technology company from answering the telephone and emails in technical support to finance to sales and business development and CEO.
He was a technology evangelist at Apple, and Director of Strategic Planning and New Business Development at NEC Computers. He was a venture capitalist and has served as VP, President and CEO of technology start-ups. In addition to launching and building technology companies around the world, he has restructured and turned around companies and he has built strategic plans for government initiatives.
He has opened new markets for businesses worldwide. He has been instrumental in landing hundreds of millions in revenue for companies, and he has been intimately involved in raising millions in venture capital for multiple ventures. He has authored technology white papers and business plans, and has performed extensive business planning from full P&Ls to operations to market launches.
At INSEAD he is an Affiliate Professor of Entrepreneurship and Family Enterprise based in Singapore. He teaches on all of INSEAD’s campuses for all programs including: MBA, GEMBA (Global Executive MBA), TIEMBA (Tsinghua INSEAD Executive MBA), and Executive Education. He continues to consult to companies around the world.
Paul is a graduate of Harvard University. He is married and has three children. He is a native English speaker, he can speak/read/write Thai, he is conversational in American Sign Language (ASL), and he has basic communication skills in a few other languages.
Professor Magill is an adjunct professor and the former Director of Science Entrepreneurship at INSEAD. He has been working with technology companies internationally for more than 25 years, from start-ups to established industry leaders. As a partner in the Silicon Valley venture fund, TeleSoft Partners, Professor Magill has invested in technology companies in the US, Europe and Israel. He has also been a senior equities analyst with Banc of America Securities, and market analyst at RHK and ElectroniCast. He started his career building laser systems at TRW, and later at Livermore National Laboratories.
“I am thrilled to participate in the Entrepreneurs in Clinical Academia initiative at INSEAD. Innovation and entrepreneurship are key to economic revival in Europe and this programme is exactly the kind of effort that fosters value creation from compelling research and invention.”
Dr Brydon Bennett has nearly 25 years of experience in pharmaceutical discovery. After starting at The Upjohn Company, he joined Signal Pharmaceuticals in 1997 as a scientist working on pro-inflammatory signal transduction. The company was purchased by Celgene in 2000. He has led multiple discovery projects, mentored project team leaders, promoted and led Inflammation & Immunology discovery research within Celgene, introduced fibrosis as a new thematic area, and set forth short and long-term strategy that was both innovative yet aligned with clinical, regulatory and commercial goals. In early 2018 he turned entrepreneur forming his own drug discovery company. Dr Bennett obtained a PhD from the University of Otago, New Zealand. He has published 50 research papers and book chapters and has been an inventor on multiple patent applications.
Carlo Pincelli is Professor of Dermatology at the School of Medicine, Biosciences and Biotechnologies, University of Modena and Reggio Emilia, Italy. He is also faculty of the PhD program in Molecular and Regenerative Medicine. He is the Director of Research at the Laboratory of Cutaneous Biology at the University of Modena and Reggio Emilia. He has been president of the European Society for Dermatological Research, and is currently Secretary General and Vice-President of the European Dermatology Forum.
Professor Pincelli is member of the Editorial Board of the Journal of Investigative Dermatology, and has published over 150 articles in international journals with contributions to areas including keratinocyte biology and autoimmune skin diseases. Professor Pincelli is the inventor/co-inventor of four international patents. He is the founder and CMO of the start-up PinCell s.r.l., which aims to research and develop novel molecules for increasing the therapeutic options in neoplastic and chronic inflammatory skin diseases.
Professor Nestle is the President of FOCIS and Director of the FOCIS Centre of Excellence at King’s College London, and Lead of the NHS National Institute for Health Research Biomedical Research Centre’s Biomarkers, Co-Diagnostics, Imaging and Devices Cluster, Guy’s and St Thomas’, King’s College London, UK. His research interests span the pathogenesis and immunotherapy of psoriasis, and the role and therapeutic modulation of dendritic cells in inflammatory and neoplastic skin diseases. He has given over 250 scientific lectures at national and international conferences, authored over 100 articles in journals including Nature and The Lancet, and has received 14 scientific prizes.
Reinhard Angelmar is Emeritus Professor of Marketing and The Salmon and Rameau Fellow of Healthcare Management, Emeritus, at INSEAD. As the creator of INSEAD’s Healthcare Compliance Implementation Leadership Programmes, he teaches in the MBA Program, has designed and directed customized programs for many biopharmaceutical companies, and carried out assignments as an expert in pharmaceutical litigation.
Professor Angelmar is the co-author of three books and a member of the Editorial Board of the International Journal of Pharmaceutical and Health Care Marketing. His articles have been published in many management journals such as the Journal of Marketing, Journal of Marketing Research, and Journal of Medical Marketing.